Effect of sarpogrelate on angiographic luminal loss and clinical outcome after endovascular treatment for peripheral artery disease

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0004511

Enrollment

Registered

2019-12-09

Start date

2020-01-31

Completion date

Unknown

Last updated

2019-12-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : -study drug : sarpogrelate hydrochloride -Product name: 100 mg of Anplag Tablet (Yuhan-Yangyang) -Use: Oral administration of 100 mg once an adult 3 times a day aspirin - product name : astri

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Patients with a newborn femoral artery lesion or a newborn knee-well (BTK) lesion with a greater than 50% stenosis; 2. Successful completion of peripheral vascular (PTA) treatment with peripheral arterial vessels (Fontaine 2, 3) or severe inferior ischemia (CLI) 3. Patients with at least 3 months of treatment after peripheral vascular treatment of antipsychotic - like aspirin + clopidogrel

Exclusion criteria

Exclusion criteria: 1. Under 18; over 85; over 85. 2. For lesions of incoming arteries: Inflow lesion: aortoilliac arterial lesion 3. In case of acute limb ischemia by thrombus 4. In the case of taboos in administering anti-platelet drugs and with thrombocytopenia (<100,000/µL) 5. Patient with liver cirrhosis of Child Class B and higher 6. Patients with anticoagulants 7. Severe heart failure (with a heart rate of less than 35% or NYHA 4) 8. If you have recently developed cerebral infarction or myocardial infarction (within 6 months) 9. Patients whose life expectancy is expected to be less than one year due to other conditions 10. Pregnant women, pregnant or nursing mothers

Design outcomes

Secondary

Measure	Time frame
?major adverse cardiovascular event, MACE-death, myocardial infarction, cerebral infarction, and resection of peripheral blood vessels?TIMI critia?CBC (Check red blood cells, platelet numbers)	—

Primary

Measure	Time frame
te luminal loss relative to baseline (peripheral angiography taken immediately after PTA procedure). Evaluation item: Peripheral angiography;?Resenosis evaluation compared to baseline (peripheral angiography taken immediately after PTA procedure).?Evaluation item: ABI evaluation compared to Peripheral angiography (SV/V1) ?SF36 evaluation compared to Baseline (SV)	—

Countries

Korea, Republic of

Contacts

Public ContactJeon Byeol

Dong-A University Hospital

wjstotquf10@naver.com+82-51-240-2573

Outcome results